TQ–Docetaxel combination (50 μM + 10 nM, respectively) increased apoptosis rate in DU145 and C4-2B prostate cancer cells by inhibiting the PI3K/AKT pathway and downstreaming signaling effectors. This evidence concerns the gene AKT1 and prostate carcinoma.